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CI NRM CI REL RFS OS
No AZA
1yr 18.7 (10.5 e 28.7) 38.6 (27.6 e 50.2) 42.9 (31.6 e 54.5) 58.6 (46.9 e 69.8)
3yrs 35.7 (24.7 e 47.4) 41.4 (30.2 e 53.1) 24.1 (14.8 e 34.8) 28.3 (18.4 e 39.4)
Yes AZA
1yr 18.1 (10.8 e 26.8) 27.0 (18.3 e 36.6) 55.1 (44.7 e 65.2) 67.4 (57.4 e 76.7)
3yrs 24.1 (15.7 e 33.5) 33.9 (24.4 e 44.0) 42.5 (32.5 e 52.9) 48.0 (37.7 e 58.4)
P¼0.05 P¼0.06
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S222Utilization of pre-HCT 5-aza is a feasible strategy and doesn’t
appear to have any negative impact on HCT outcomes. Given
the beneﬁcial disease control facilitated by aza it should be
offered to patients with high risk MDS being considered for
a HCT.342
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Background: In spite of modern antimicrobial and sup-
portive therapy, bacterial and fungal infections are still major
complications in patients with profound neutropenia. For
decades, the value of granulocyte transfusion (GTX) has been
explored and results are still not conclusive. Neutropenia
caused by transplant conditioning regimens in patients who
fail to respond to antimicrobial agents is one of the most
common indications for GTX.
Objective: The purpose of this study was to analyze out-
comes and risk factors for survival in patients who received
GTX.
Patients and Methods: a retrospective analysis was per-
formed on all patients submitted allogeneic hematopoietic
cell transplantation (HSCT) who received GTX from january
2006 to april 2013 in our center. We analyzed patients
characteristics, survival and identiﬁed risk factors for sur-
vival. Statistical analyses were performed using Graphpad
Prism version 6.0. Fisher exact test was used to compare
categoric variables and Kaplan-Meyer to evaluate survival.
P level signiﬁcance was < 0,05.
Results: We investigate the efﬁcacy of GTX into 32 patients
with severe neutropenia and fungal and/or bacterial in-
fections. There were 50% (n¼ 16) females and 50% (n¼ 16)
males. Of these, 46,8% (n¼ 15) were adults. Twenty-ﬁve
percent of patients (n¼ 8) had genetic diseases, 43,8% (n¼
14) had severe aplastic anemia and 31,2% (n¼ 10) had other
malignant hematological diseases. A total of 196 GTX were
perfomed. The average number of transfusion by patient was
6,125. The average number of granulocyte count in each bag
was 3,84x1010. Every patients had neutrophil count at the
hemogram below 100/mm3 and had unresponsive severe
infection to antimicrobial and antifungal treatment at the
day of the ﬁrst GTX. In the period of infection, 56,3% (n¼ 18)
had bacteria identiﬁed by culture: 61,1% (n¼ 11) gram-posi-
tive and 38,8% (n¼ 7) gram-negative; and 65,6% hadpresumed or conﬁrmed fungal infection: 33,4% (n¼ 7)
Fusarium sp, 38,1% (n¼ 8) Aspergillus sp, 9,5% (n¼ 2) Candida
sp, 19% (n¼ 4) probable invasive fungal disease). Five patients
received only one GTX before dying. Median survival for the
whole cohort was 103 days. There was no signiﬁcant differ-
ence in survival according to age, disease, number of GTX
received and donor source. In bivariate analysis, patients
with age higher than 14 years old and patients who received
less than ﬁve transfusions had higher chance of death
(p¼0,015, OR-7,3 and p¼0,03, OR-3,61 respectively).
Conclusion: GTX may have an adjunctive role in severe in-
fections in patients with profound neutropenia submitted to
HSCT. Children and more than ﬁve GTX were protective
factors. GTX is an underutilized supportive modality for
critically ill patients undergoing allogeneic HSCT and it
seems to bring beneﬁts in some groups of patients. Pro-
spective randomized studies are necessary to a better eval-
uation of this procedure.343
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Cytomegalovirus (CMV) infection is a major cause of
morbidity and mortality following allogeneic stem cell
transplantation (SCT). We wanted to study the incidence of
CMV reactivation following SCT is high in a populationwhere
previous exposure to CMV is high. This is a retrospective
analysis of consecutive transplants done in the Department
of Haematology, Christian Medical College, Vellore India
between January 2008 and December 2012. Recipient and
donor demographics along with transplant data were
recorded. Patients were monitored for CMV reactivation
weekly using a CMV DNA PCR in the ﬁrst 100 days post SCT.
Four hundred and seventy ﬁve patients with a median age of
21 years (range: 1-59) underwent SCT for both malignant
and non-malignant indications. Of these, 459 (97.2%) were
CMV IgG positive. Donors were either sibling (n ¼ 393) or
matched unrelated (n¼ 82). CMV reactivation occurred in
36.6% at a median time of 41 days post SCT (range: 10 - 100).
CMV disease occurred in 8 patients (1.68%). The use of a male
donor (p¼0.000), unrelated donor (p¼0.000), degree of HLA
mismatch (p¼0.000), neutrophil recovery <15 days
(p¼0.005), acute GVHD (p¼0.000) and steroid refractory
GVHD (p¼0.028) were identiﬁed as risk factors for CMV
reactivation on univariate analysis. On multivariate analysis
degree of HLA mismatch (p¼0.009), early neutrophil recov-
ery (p¼0.014) and steroid refractory GVHD (p¼0.014)
remained independent risk factors. Most of the patients were
treated with ganciclovir for a median duration of 16 days (14
e 21). The 5 year overall survival was signiﬁcantly lower in
Variable HR 95% CI P-value
RPA group
G1 (no cytoreduction) 1
G2 (Cytoreduction w/
stable/decreasing blasts)
1.15 0.45-2.98 0.77
G3 (Cytoreduction w/ 3.03 1.11-8.28 0.03
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S223patients who had CMV reactivation (58.2  4.9%) compared
to patients without reactivation (68.9  3.7%, p¼0.004).
The incidence of CMV reactivation after SCT is low despite a
high seroprevalence in Indian patients undergoing allogeneic
SCT. CMV reactivation however is associated with a lower
overall survival following allogeneic SCT.increasing blasts)
De novo vs. secondary MDS 3.52 1.07-11.6 0.039
LDH >330 IU/L at HCT 2.69 1.26-5.73 0.01
Blasts at HCT (continuous) 1.05 0.98-1.12 0.16
HCT-CI score
Int vs. Low 1.43 0.62-3.32 0.4
High vs. Low 0.97 0.39-2.45 0.95344
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Background:Many patients with myelodysplastic syndrome
(MDS) undergo cytoreductive chemotherapy to reduce the
marrow blast count prior to allogeneic hematopoietic cell
transplantation (HCT). While pre-HCT disease burden cor-
relates with post-HCT outcome, a dynamic approach of
assessing changes in blast count with therapy has not been
systematically explored.
Methods: Results of 54 consecutive patients transplanted
between 2005-2012 for MDS (43 de novo, 11 secondary) with
full-intensity conditioning regimens (94% with busulfan
/cyclophosphamide) were analyzed. The median age was 50
years (range 20-66). Donors were siblings (33%) or unrelated
(67%); 78% of patients received marrow and 22% peripheral
blood progenitor cells. Recursive partitioning analysis (RPA)
was used to identify groups that are prognostic for overall
survival (OS) based on pre-HCT chemotherapy and change in
blast count. The association of RPA group with outcome was
examined.
Results: RPA identiﬁed three groups: patients who did not
receive pre-HCT cytoreduction (G1), those who did with
subsequent stable/decreased (G2) or increased (G3) blast
count prior to HCT. These groupswere similar with respect to
demographic, disease, and transplant variables, as well as
comorbidity scores (HCT-CI).
Though the grade and incidence of GVHD and relapse
were similar, OS (Figure, P ¼ 0.02, log-rank) and NRM (P ¼
0.08, Gray test) were inferior for patients who had an in-
crease in blast count after pre-HCT cytoreduction. Three-year
OS was 54%, 43%, and 12%, respectively, for G1, G2, and G3;
3-year NRM was 31%, 34%, and 81%. Mortality at 100 days
was 23%, 7%, and 46% for G1, G2, and G3, respectively (P ¼
0.16). A clear pattern for cause of NRM in G3 versus G1/G2
could not be discerned.
Pre-HCT blast count and comorbidities were not associ-
ated with OS in univariate analysis (Table). In multivariate
analysis, pre-HCT chemotherapy with an increase in blast
count remained associated with a worse survival relative to
no prior chemotherapy (HR 3.08, 95% CI 1.13-8.43, P ¼ 0.028.
Conclusions: Counterintuitively, the inferior survival of G3
was not due to relapse, but mainly NRM, particularly early
mortality, despite similar HCT-CI scores. This result suggests
that thosewho progress despite pre-HCTchemotherapy with
an unacceptably high risk of NRM, may not beneﬁt from HCT.This analysis cannot determine if pre-HCT cytoreduction is
beneﬁcial or detrimental, and should be carefully assessed in
prospective studies.
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Background: CMV infection remains an important cause of
morbidity & mortality in CBT recipients. The objective of this
study was to determine the incidence and to examine the
characteristics & outcome of CMV infections in 95 CBT
recipients.
Methods:We identiﬁed CBT recipients whowere cared for at
our institution between 2000 & 2007 from the Stem Cell
Transplant databases. Data on demographics, underlying
cancer, risk factors for CMV reactivation, CMV prophylaxis,
CMV serostatus & outcomes were collected. Multivariate lo-
gistic regression analyses (MVA) were applied to identify
